4NG9 image
Entry Detail
PDB ID:
4NG9
Title:
Factor viia in complex with the inhibitor (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-[3-ethoxy-4-(propan-2-yloxy)phenyl]-n-(3-sulfamoylbenzyl)ethanamide
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2013-11-01
Release Date:
2014-01-08
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.22
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 41 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Factor VIIa (Heavy Chain)
Chain IDs:A (auth: H)
Chain Length:254
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Factor VIIa (Light Chain)
Chain IDs:B (auth: L)
Chain Length:55
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors.
ACS Med Chem Lett 5 188 192 (2014)
PMID: 24900796 DOI: 10.1021/ml400453z

Abstact

Inhibitors of the Tissue Factor/Factor VIIa (TF-FVIIa) complex are promising novel anticoagulants that show excellent efficacy and minimal bleeding in preclinical models. On the basis of a zwitterionic phenylglycine acylsulfonamide 1, a phenylglycine benzylamide 2 was shown to possess improved permeability and oral bioavailability. Optimization of the benzylamide, guided by X-ray crystallography, led to a potent TF-FVIIa inhibitor 18i with promising oral bioavailability, but promiscuous activity in an in vitro safety panel of receptors and enzymes. Introducing an acid on the pyrrolidine ring, guided by molecular modeling, resulted in highly potent, selective, and efficacious TF-FVIIa inhibitors with clean in vitro safety profile. The pyrrolidine acid 20 showed a moderate clearance, low volume of distribution, and a short t 1/2 in dog PK studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures